169 related articles for article (PubMed ID: 28634142)
1. Cysteamine polysaccharide hydrogels: Study of extended ocular delivery and biopermanence time by PET imaging.
Luaces-Rodríguez A; Díaz-Tomé V; González-Barcia M; Silva-Rodríguez J; Herranz M; Gil-Martínez M; Rodríguez-Ares MT; García-Mazás C; Blanco-Mendez J; Lamas MJ; Otero-Espinar FJ; Fernández-Ferreiro A
Int J Pharm; 2017 Aug; 528(1-2):714-722. PubMed ID: 28634142
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo ocular safety and eye surface permanence determination by direct and Magnetic Resonance Imaging of ion-sensitive hydrogels based on gellan gum and kappa-carrageenan.
Fernández-Ferreiro A; González Barcia M; Gil-Martínez M; Vieites-Prado A; Lema I; Argibay B; Blanco Méndez J; Lamas MJ; Otero-Espinar FJ
Eur J Pharm Biopharm; 2015 Aug; 94():342-51. PubMed ID: 26079831
[TBL] [Abstract][Full Text] [Related]
3. Ophthalmic Econazole Hydrogels for the Treatment of Fungal Keratitis.
Díaz-Tomé V; Luaces-Rodríguez A; Silva-Rodríguez J; Blanco-Dorado S; García-Quintanilla L; Llovo-Taboada J; Blanco-Méndez J; García-Otero X; Varela-Fernández R; Herranz M; Gil-Martínez M; Lamas MJ; González-Barcia M; Otero-Espinar FJ; Fernández-Ferreiro A
J Pharm Sci; 2018 May; 107(5):1342-1351. PubMed ID: 29305870
[TBL] [Abstract][Full Text] [Related]
4. In vivo eye surface residence determination by high-resolution scintigraphy of a novel ion-sensitive hydrogel based on gellan gum and kappa-carrageenan.
Fernández-Ferreiro A; Silva-Rodríguez J; Otero-Espinar FJ; González-Barcia M; Lamas MJ; Ruibal A; Luaces-Rodríguez A; Vieites-Prado A; Lema I; Herranz M; Gómez-Lado N; Blanco-Mendez J; Gil-Martínez M; Pardo M; Moscoso A; Cortes J; Sánchez-Martínez M; Pardo-Montero J; Aguiar P
Eur J Pharm Biopharm; 2017 May; 114():317-323. PubMed ID: 28189624
[TBL] [Abstract][Full Text] [Related]
5. Positron Emission Tomography for the Development and Characterization of Corneal Permanence of Ophthalmic Pharmaceutical Formulations.
Fernández-Ferreiro A; Silva-Rodríguez J; Otero-Espinar FJ; González-Barcia M; Lamas MJ; Ruibal A; Luaces-Rodriguez A; Vieites-Prado A; Sobrino T; Herranz M; García-Varela L; Blanco-Mendez J; Gil-Martínez M; Pardo M; Moscoso A; Medín-Aguerre S; Pardo-Montero J; Aguiar P
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):772-780. PubMed ID: 28146242
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Cysteamine Delivery Nanowafer as an Efficacious Treatment Modality for Corneal Cystinosis.
Marcano DC; Shin CS; Lee B; Isenhart LC; Liu X; Li F; Jester JV; Pflugfelder SC; Simpson J; Acharya G
Mol Pharm; 2016 Oct; 13(10):3468-3477. PubMed ID: 27571217
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of corneal drug delivery of cysteamine using vitamin E modified silicone hydrogel contact lenses.
Hsu KH; Fentzke RC; Chauhan A
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):531-40. PubMed ID: 23665502
[TBL] [Abstract][Full Text] [Related]
8. Gel formulations for treatment of the ophthalmic complications in cystinosis.
Buchan B; Kay G; Heneghan A; Matthews KH; Cairns D
Int J Pharm; 2010 Jun; 392(1-2):192-7. PubMed ID: 20382212
[TBL] [Abstract][Full Text] [Related]
9. A sustained release cysteamine microsphere/thermoresponsive gel eyedrop for corneal cystinosis improves drug stability.
Jimenez J; Washington MA; Resnick JL; Nischal KK; Fedorchak MV
Drug Deliv Transl Res; 2021 Oct; 11(5):2224-2238. PubMed ID: 33543397
[TBL] [Abstract][Full Text] [Related]
10. [Cysteamine ophthalmic hydrogel for the treatment of ocular cystinosis].
Fernández-Ferreiro A; Luaces-Rodríguez A; Díaz-Tomé V; Gil-Martínez M; Rodríguez Ares MT; Touriño Peralba R; Blanco-Méndez J; González-Barcia M; Otero-Espinar FJ; Lamas MJ
Farm Hosp; 2017 Nov; 41(6):678-687. PubMed ID: 29112493
[TBL] [Abstract][Full Text] [Related]
11. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
[TBL] [Abstract][Full Text] [Related]
12. A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.
Liang H; Labbé A; Le Mouhaër J; Plisson C; Baudouin C
Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2275-2283. PubMed ID: 28426870
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug release and in vivo safety of vitamin E and cysteamine loaded contact lenses.
Dixon P; Fentzke RC; Bhattacharya A; Konar A; Hazra S; Chauhan A
Int J Pharm; 2018 Jun; 544(2):380-391. PubMed ID: 29217475
[TBL] [Abstract][Full Text] [Related]
14. [Cysteamine eyedrops for treatment of corneal cysteine deposits in infantile cystinosis].
Gräf M; Grote A; Wagner F
Klin Monbl Augenheilkd; 1992 Jul; 201(1):48-50. PubMed ID: 1513127
[TBL] [Abstract][Full Text] [Related]
15. Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration.
Abrego G; Alvarado H; Souto EB; Guevara B; Bellowa LH; Parra A; Calpena A; Garcia ML
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):261-70. PubMed ID: 25681744
[TBL] [Abstract][Full Text] [Related]
16. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of topical cysteamine in nephropathic cystinosis.
Al-Hemidan A; Shoughy SS; Kozak I; Tabbara KF
Br J Ophthalmol; 2017 Sep; 101(9):1234-1237. PubMed ID: 28057644
[TBL] [Abstract][Full Text] [Related]
18. Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.
Castro-Balado A; Bandín-Vilar E; Cuartero-Martínez A; García-Quintanilla L; Hermelo-Vidal G; García-Otero X; Rodríguez-Martínez L; Mateos J; Hernández-Blanco M; Aguiar P; Zarra-Ferro I; González-Barcia M; Mondelo-García C; Otero-Espinar FJ; Fernández-Ferreiro A
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297629
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceutical Assessment of Dexamethasone Acetate-Based Hydrogels Combining Hydroxypropyl Cyclodextrins and Polysaccharides for Ocular Delivery.
Mazet R; García-Otero X; Choisnard L; Wouessidjewe D; Verdoot V; Bossard F; Díaz-Tomé V; Blanc-Marquis V; Otero-Espinar FJ; Fernandez-Ferreiro A; Gèze A
Pharmaceutics; 2020 Jul; 12(8):. PubMed ID: 32751583
[TBL] [Abstract][Full Text] [Related]
20. Preformulation of cysteamine gels for treatment of the ophthalmic complications in cystinosis.
McKenzie B; Kay G; Matthews KH; Knott R; Cairns D
Int J Pharm; 2016 Dec; 515(1-2):575-582. PubMed ID: 27771488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
